Quarterly Updates14 Nov 2025, 02:57 pm
Advik Laboratories Reports Q2 & H1 FY2025 Results with Net Loss of ₹ 43.53 Crore
AI Summary
Advik Laboratories Ltd. has announced its financial results for the quarter and half year ended 30th September 2025. The company reported a net loss of ₹ 43.53 Crore for Q2 and ₹ 88.81 Crore for H1. The audit committee and board of directors have reviewed the unaudited financial results. The company is awaiting renewal of its Drug Manufacturing Licenses and is working to restart its business operations with new deals and market opportunities.
Key Highlights
- Net loss of ₹ 43.53 Crore for Q2 and ₹ 88.81 Crore for H1
- The company is awaiting renewal of its Drug Manufacturing Licenses
- Management is working to restart business operations with new deals and market opportunities
- Audit committee and board of directors have reviewed the unaudited financial results
- Company has not paid the Annual Listing Fees (ALF) of the Bombay Stock Exchange Limited (BSE) since the financial year 2021-22